Two Years to the EAEU Medical Device Deadline: Why Delaying Migration Is Already Risky
At the end of December 2025, the member states of the Eurasian Economic Union (EAEU) signed a protocol extending the transition period for medical devices until December 31, 2027.
Manufacturers exhaled. Two years will pass quickly, and the volume of work required to migrate to the unified rules has not shrunk by a single page. Those who postpone preparation until 2027 risk losing the right to sell their products across five countries.
This article covers why waiting is dangerous, what requirements must be met, and how to plan migration without ending up in a testing queue alongside everyone else.
How the Old System Worked
Before unified EAEU rules existed, each member state registered medical devices (MDs) under its own national legislation: Russia under Government Decree No. 1416 (2012), Kazakhstan under Ministry of Health orders, Belarus under a third system with its own specifics. A manufacturer wishing to operate across the entire EAEU had to undergo registration in each country separately.
The system was predictable but inefficient: five separate procedures, five sets of documents, five sets of state fees. For large international companies, that meant excessive overhead; for smaller ones, it was a barrier to entry into neighboring markets.
Example: A German manufacturer of X-ray equipment wishing to sell in Russia, Kazakhstan, and Belarus spent up to three years and several million rubles navigating three concurrent registration procedures.
The national procedure in Russia, despite its relative simplicity, had real limitations. The Marketing Authorization (MA) was valid indefinitely but only within the Russian Federation. Evidence requirements were softer. In many cases, submitting literature data on analogous devices was sufficient instead of conducting original clinical investigation. Manufacturing inspections were not mandatory for most device classes.
The agreement on unified principles and rules for MD circulation within the EAEU was signed in December 2014. The document established the intent to create a common MD market with a single registration procedure and mutual recognition of authorizations.
In 2016, the Council of the Eurasian Economic Commission (EEC) adopted a package of decisions forming the regulatory framework:
Decision No. 46: Rules for Registration and Expertise of Safety, Quality, and Efficacy.
Decision No. 27: General Safety and Performance Requirements (GSPR).
Decision No. 29: Rules for Clinical Investigation.
Regulators initially planned for all countries to transition to the common procedure by 2021. Deadlines shifted several times. The original date of December 31, 2021 moved to 2025, and has now been extended again to 2027. The reasons are clear: manufacturers were unprepared, testing laboratories were overloaded, and EAEU requirements are substantially more stringent than national ones. The COVID-19 pandemic redirected regulator resources toward urgent authorization of protective equipment and diagnostic tests, pushing planned migration work aside.
The Protocol of December 29, 2025
The EAEU states signed a protocol amending the Agreement on Unified Principles and Rules for Medical Device Circulation. The document allows submission of applications for expertise and registration until December 31, 2027 under either Union law or a member state’s national legislation.
Previously, this mechanism was set to expire on December 31, 2025, after which the plan was a full transition to EAEU-only registration. MDs registered under national rules may be re-registered under national procedures provided the application is submitted by December 31, 2028.
Table 1. Changes to the Medical Device Transition Period
| Parameter | Before the Protocol | After the Protocol |
|---|---|---|
| Last day to apply for national MA | Dec 31, 2025 | Dec 31, 2027 |
| Deadline for national MA re-registration | — | Dec 31, 2028 |
| Mandatory EAEU-only transition | Jan 01, 2026 | Jan 01, 2028 |
| Validity of national MAs issued before deadline | Until expiration | Until expiration |
Manufacturers and suppliers in Kazakhstan, Russia, Belarus, Armenia, and Kyrgyzstan now have until the end of 2027 to choose: register MDs under old national requirements or under the new unified EAEU rules.
Choosing the national route has limited strategic value. A national MA is valid in one country only, and after 2028 the system will fully transition to unified rules. Registering nationally in 2027 means repeating the entire process under EAEU rules a few years later.
When National Procedure Still Makes Sense
There are scenarios where national registration in 2026–2027 is justified:
Urgent single-market entry. If a company needs to start sales in Russia within six months and the EAEU dossier is not ready, national registration can serve as a transitional measure (tactical, not strategic).
Short product life cycle. If a product is planned for discontinuation in three to four years, the full investment in EAEU registration may not pay off.
Low-risk Class 1 devices for one country. For simple devices sold only in Russia, the complexity difference between procedures is minimal.
In all other cases, EAEU registration is the right choice.
Why Waiting Until 2027 Is Dangerous
Risk Classification Determines Workload
The Rules for Classification of Medical Devices by Potential Application Risk (EEC Decision No. 55) divide all MDs into four classes. Devices of Classes 2b and 3 represent a substantial portion of the market by value and will create the heaviest infrastructure load during mass migration.
Table 2. MD Classification by Risk Level and EAEU Procedure Scope
| Class | Risk Level | Examples | EAEU Procedure Scope |
|---|---|---|---|
| 1 | Low | Crutches, corrective eyewear, bandages | Minimal: technical testing, expertise |
| 2a | Medium | Hearing aids, infusion sets, surgical gloves | Moderate: plus toxicology for contact devices |
| 2b | High | Defibrillators, X-ray units, ventilators | Full: plus QMS inspection, clinical data |
| 3 | Highest | Implants, stents, drug-coated devices | Maximum: plus clinical investigation within EAEU |
Limited Testing Laboratory Capacity
In Russia, there are only a few dozen accredited laboratories capable of conducting EAEU-compliant MD testing. Each can process a limited number of devices per year. Roszdravnadzor’s state register currently holds over 50,000 MDs registered under the national procedure.
As of January 2026, queues for toxicological testing at leading centers (VNIIIMT, TsMIKEE in Moscow) already run 3–4 months. By mid-2027, when thousands of companies rush to meet the deadline, wait times could reach 10–12 months, making it practically impossible to complete registration before the transition period closes.
The most constrained area is toxicology and biocompatibility. EEC Council Decision No. 38 on Rules for Biological Safety Assessment establishes detailed requirements for toxicological study protocols. Unlike FDA or European Notified Body practice (where biocompatibility evaluation based on chemical characterization and literature data without animal testing is often accepted), EAEU experts require actual in vitro and in vivo testing on the finished device in more than 85% of cases for patient-contacting devices. The number of vivaria and laboratories accredited for the full test scope under Decision No. 38 and GOST ISO 10993 is limited.
Shortage of Manufacturing Inspectors
EAEU registration for Classes 2a (sterile), 2b, and 3 requires mandatory manufacturing inspection for Quality Management System (QMS) compliance under EEC Council Decision No. 106 of November 10, 2017. This covers a substantial share of the market: surgical instruments, implants, diagnostic equipment, sterile disposables.
The number of accredited inspectors is limited, and a single manufacturing inspection takes several days. If everyone arrives in the final year, inspection queues will stretch for many months as well.
Rising Costs Under Surge Demand
When demand exceeds supply, prices follow. Laboratory testing costs will predictably increase by the end of 2026. Consulting firms that help prepare EAEU registration documentation are already booked months ahead, and qualified MD regulatory specialists are almost entirely unavailable on the open market.
What EAEU Registration Actually Requires
Technical File Instead of a Registration Dossier
Under the national procedure, manufacturers submitted a document package consisting largely of descriptions and declarations. EAEU rules require a complete technical file whose structure mirrors the European approach.
The technical file must include:
- Evidence of compliance with the GSPR (EEC Decision No. 27)
- Risk management results per ISO 14971
- Full description of design, materials, and manufacturing technology
- Verification and validation results
- Biocompatibility data for patient-contacting devices
- Clinical evidence of safety and efficacy
- Instructions for use and labeling in member state languages
If the central document in Russia’s national procedure was Technical Specifications (ТУ) describing specific device parameters, the central element of the EAEU system is the GSPR compliance checklist per Decision No. 27. The GSPR contains hundreds of items covering chemical, physical, and biological properties, sterility, software, labeling, and ergonomics. Against each item, the manufacturer must reference a specific standard (preferably from the list of GOST standards harmonized with EAEU) and the confirming document: a test report number, validation report. «Not applicable» without technical justification will generate an expert query.
Documents prepared for national registration must almost always be rebuilt from scratch. Formal compliance with the Roszdravnadzor checklist does not equal compliance with the EAEU technical file.
The most significant changes concern biological safety evidence. Decision No. 38 requires actual testing (in vitro and in vivo) on the finished device. Old toxicology protocols from five years ago may be insufficient. Laboratories conducting these studies must be listed in the EAEU Unified Register of Authorized Organizations — studies performed at non-accredited laboratories are not accepted.
QMS under EEC Decision No. 106
For Classes 2a (sterile), 2b, and 3, the registration dossier must include copies of QMS compliance certificates against ISO 13485 (or equivalent national/international standard) and copies of prior inspection reports against ISO 13485, if available.
Manufacturers who already have an ISO 13485-based QMS have a clear advantage. Roszdravnadzor has indicated that those with ISO 13485 in place will face a simplified inspection process. If no QMS exists, implementation takes four to twelve months, with six months as the recommended minimum.
There is an important distinction between ISO 13485 certification and an EAEU inspection.
Table 3. ISO 13485 Audit vs. EAEU Manufacturing Inspection (Decision No. 106)
| Parameter | ISO 13485 Audit (certification body) | EAEU Inspection (Decision No. 106) |
|---|---|---|
| Purpose | System conformance | Conformance of production to the registration dossier |
| Focus | Processes (CAPA, document control) | Product (process maps, line QC) |
| Result | Compliance certificate | Inspection report for registration |
| Depth | Sampling-based | Detailed examination of the specific device file |
EAEU inspectors arrive at the facility with a copy of the technical file submitted for registration. If the file states that sterility control is performed by membrane filtration and the plant actually uses direct inoculation, the discrepancy results in registration refusal.
Clinical Investigation
One of the most significant differences between EAEU rules and national procedures concerns clinical data.
For Class 3, Class 2b, and implantable MDs, clinical investigation for registration purposes must be conducted as multicenter studies meeting specified conditions. For devices whose clinical investigation began after January 1, 2022, at least one of the studies must be conducted on the territory of an EAEU member state. This covers high-risk device classes: implants, invasive devices, active implantable devices.
If a device falls into these classes and was previously registered on the basis of literature data or studies conducted exclusively abroad, clinical investigation in Russia, Kazakhstan, or another EAEU country must be planned, adding six to twelve months to the registration timeline.
The equivalence problem. Claiming equivalence to a competitor’s device is straightforward on paper; proving it within the EAEU framework is not. The regulator requires confirmation of technical, biological, and clinical equivalence. Without access to the competitor’s confidential technical documentation (drawings, material compositions), proving biological and technical identity is practically impossible. The only reliable path for equivalence-based claims is reference to the manufacturer’s own earlier models (predicates). In all other cases, it is safer to plan independent clinical investigation or compile exhaustive literature data.
IVD Specifics
In vitro diagnostic (IVD) devices follow different rules. IVDs are exempt from patient-enrolled clinical investigation in the conventional sense but require clinical-laboratory testing (performance evaluation). This involves comparing the tested reagent kit against a reference kit already registered in the EAEU. Laboratories conducting such testing must have access to verified clinical samples (biobanks) with known pathologies. A shortage of such samples at accredited EAEU centers creates additional delays.
Selecting a Reference Member State
Under the EAEU procedure, registration begins in one country (the Reference Member State), which conducts the expertise and issues the MA. Other states then recognize the MA and enter the device in their registries.
Table 4. Reference Member State Selection for EAEU Registration
| State | Advantages | Considerations | When to Choose |
|---|---|---|---|
| Russia | Largest market, high expert qualification, developed lab base | High Roszdravnadzor workload, longer expertise timelines | When Russia is the primary target market |
| Kazakhstan | Faster primary expertise timelines, actively developing regulatory system | Less experience with certain complex device categories | As a «gateway» for foreign manufacturers |
| Belarus | Developed expert base, experience in pharma and adjacent areas | Specific administrative procedure features | For CIS manufacturers with established ties |
| Armenia | Relatively lighter expert workload | Limited laboratory capacity | For simple, lower-risk devices |
| Kyrgyzstan | Light workload, potentially faster timelines | Least experience with the EAEU procedure | With caution, for straightforward devices |
Many foreign manufacturers choose Kazakhstan or Belarus as their EAEU «gateway» because of shorter timelines, then obtain recognition in Russia and other countries afterward.
The expertise in the Reference Member State must be thorough. If experts miss a dossier deficiency, other states may identify the issue during recognition, leading to registration suspension and a requirement for additional testing.
The Recognition Refusal Risk
A scenario no regulatory manager wants to face: the Reference Member State (say, Belarus) issues a positive assessment, and the Recognized State (say, Russia) refuses to concur.
This happens during the expert opinion conciliation process. Grounds for refusal are defined in the rules but interpreted broadly: insufficient clinical evidence in the view of the Recognized State’s experts, labeling non-compliance with national requirements, failure to respond to additional queries within the set deadline.
If consensus is not reached, the device is registered only in the countries that agreed. This strips the manufacturer of EAEU’s main advantage and effectively returns the situation to multiple national registrations.
For foreign manufacturers, an authorized representative for medical devices within the EAEU is mandatory. The representative submits documents, communicates with regulators, and bears responsibility for the device on the market. Selecting a reliable representative with direct experience in the EAEU procedure (not just national registration) has a material effect on outcomes.
How Long EAEU Registration Takes
Table 5. Minimum EAEU Registration Timeline for Class 2b/3 Devices
| Stage | Duration |
|---|---|
| Technical file preparation | 3–6 months |
| QMS implementation (if absent) | 4–6 months |
| Technical testing | 1–3 months |
| Toxicological studies | 2–4 months |
| Clinical investigation (if required) | 6–12 months |
| Manufacturing inspection (incl. preparation and report receipt) | 2–4 months |
| Expertise at the authorized body | 2–4 months |
| Recognition in other states | 1–2 months |
With parallel execution of some stages, the total timeline for a complex device ranges from 12 to 24 months.
For Class 1 and non-sterile Class 2a devices the procedure is simpler — no manufacturing inspection required, smaller testing volume. Even so, a realistic timeline from start of preparation to MA receipt is 6–12 months.
What Waiting Actually Costs
Scenario 1. Start now (January 2026)
Table 6. Costs under Scenario 1 (Starting January 2026)
| Cost Item | Amount |
|---|---|
| QMS implementation | 800,000–1,500,000 RUB (~$8,900–$16,700) |
| ISO 13485 certification | 200,000–400,000 RUB (~$2,200–$4,400) |
| Technical testing | 400,000–1,200,000 RUB (~$4,400–$13,300) |
| Toxicology/biocompatibility | 160,000–500,000 RUB (~$1,800–$5,600) |
| Manufacturing inspection (incl. inspector travel) | 1,200,000–2,000,000 RUB (~$13,300–$22,200) |
| State fees and documentation preparation | 500,000–1,000,000 RUB (~$5,600–$11,100) |
| Consulting and translation | 800,000–1,600,000 RUB (~$8,900–$17,800) |
| Total | 4,000,000–8,200,000 RUB (~$44,000–$91,000) |
If clinical investigation is required (Classes 2b and 3), add 1,600,000–8,000,000 RUB (~$18,000–$89,000) depending on complexity.
Scenario 2. Start January 2027
Table 7. Impact of Surge Demand on Costs (Scenario 2, January 2027)
| Factor | Impact on Cost |
|---|---|
| QMS implementation | +30–50% due to consultant shortage |
| Testing | +50–100% due to queues and urgency premiums |
| Inspection | +30% due to elevated demand |
| Consulting | +40–60% due to specialist overload |
Total: 6,000,000–13,000,000 RUB (~$67,000–$144,000)
The larger cost is time, not money. Filing an application in January 2027 and joining a testing queue that stretches 10–12 months means the MA will not arrive before the transition period closes. For a company with 100,000,000 RUB (~$1.1 million) in annual turnover, even three months of lost sales across the EAEU means ~25,000,000 RUB (~$278,000) in foregone revenue — far exceeding any savings from delaying registration.
What Regulatory Departments Should Do in 2026
1. Portfolio audit. Divide all devices into three groups. Green zone: devices that are clearly needed across EAEU markets and for which EAEU registration is economically justified (migration priority). Yellow zone: devices requiring economic feasibility analysis; some products may be better discontinued in certain countries. Red zone: aging devices, low-volume sellers, or products planned for discontinuation. No point spending migration resources there.
2. QMS readiness assessment. Determine whether ISO 13485 is in place, when the last audit occurred and what findings it produced, and if not in place, how long implementation will take. Cross-check the existing QMS against EAEU requirements (Decision No. 106) regardless of ISO 13485 certification status.
3. Documentation gap analysis. For each green-zone device, identify which documents can be reused in the EAEU technical file, which require rework, which are missing entirely, and which testing must be repeated. Pay particular attention to risk management documentation (ISO 14971), biocompatibility evidence for patient-contacting devices, and clinical data.
4. Book laboratory slots. Do not wait until the full documentation package is ready. Contact accredited testing laboratories now and schedule testing for autumn 2026 or Q1 2027. Laboratories accredited for EAEU-compliant MD testing include FSBI VNIIIMT of Roszdravnadzor, FSBI NTsESMP of the Ministry of Health, and other laboratories listed in the EAEU Unified Register of Authorized Organizations (current list available on the Roszdravnadzor website and the EAEU portal).
5. Choose a Reference Member State and authorized representative. For foreign manufacturers, an authorized representative for medical devices is mandatory. Select a partner with direct EAEU procedure experience, not only national registration experience. Choose the Reference Member State based on practical factors: where queues are shorter, where you have a reliable partner, which market is the priority.
6. Build a roadmap with firm deadlines.
Table 8. Sample Roadmap for a Class 2b Device
| Period | Task |
|---|---|
| January–March 2026 | Portfolio audit, gap analysis, Reference Member State selection |
| April–June 2026 | Document remediation, laboratory booking |
| July–September 2026 | Technical and toxicological testing |
| October–December 2026 | Manufacturing inspection, dossier assembly |
| January–March 2027 | Registration application submission |
| April–September 2027 | Expertise, responding to queries |
| October–December 2027 | MA receipt, recognition procedure |
This schedule preserves buffer time for unexpected developments: regulator queries, additional testing requirements, laboratory delays.
Risks of Inaction
After January 1, 2028, only MDs holding MAs issued under the EAEU unified rules will circulate across the Union. National MAs that have not yet expired will remain valid, but modifications under the national procedure will not be permitted.
For manufacturers with national MAs: no expansion of indications without transitioning to EAEU, no change of manufacturing site, gradual market attrition as MA expiry dates arrive, and no device modification even if core characteristics are preserved.
For new devices: no market access without EAEU registration, and no fast-track national procedure alternative.
For public procurement participants: major tenders already require confirmation of current or pending EAEU registration, and by 2027 that requirement will be universal.
For distributors: risk of holding product that cannot legally be sold, need to revise supplier contracts, and a shift toward manufacturers who have already completed EAEU registration.
Common Mistakes
Registering nationally in 2026–2027 to «buy time.» The national MA will have a limited lifespan, after which the EAEU procedure must be repeated. Double the work, double the cost. The exception described above (urgent single-market entry with a short product life cycle) is narrow.
Using CE-marking documentation for EAEU without adaptation. EAEU requirements and the European MDR/IVDR share common roots but differ substantially in specifics. Clinical data accepted in Europe is not automatically accepted by EAEU experts without additional justification. The technical file must be adapted, not merely translated.
Underestimating QMS requirements. An ISO 13485 certificate does not guarantee a successful EAEU inspection. Roszdravnadzor inspectors evaluate actual process execution, not just document existence. Companies with ISO 13485 certificates from international certification bodies have received substantive findings at EAEU inspections.
Counting on another deadline extension. The EEC has described the current extension as enabling member states to optimize national registration systems and ensure a smooth transition. The language suggests this extension is intended to be the final one. Planning for a fourth deadline shift is not a prudent strategy.
Handling the process without experienced consultants. The EAEU procedure is more complex than the national one. A company that previously managed national registration with a single in-house specialist may lose months learning EAEU requirements through trial and error. An experienced consultant pays for itself in time saved and reduced refusal risk.
Submitting dossiers with incomplete clinical data and expecting to resolve the gaps through discussion. National registration practice, where evidential shortfalls were sometimes compensated through informal expert engagement, does not carry over to the EAEU procedure. Requirements are formalized, criteria are transparent, and decisions are made based on the dossier. Insufficient evidence leads to queries, delays, and potential refusal.
Overlooking translation requirements. The dossier must be submitted in the member state languages: Russian for Russia; Kazakh and Russian for Kazakhstan; others as required. Technical translation of specialized documentation takes time and competent translators. Poor-quality translation generates expert queries and delays.
Exchange rate used for dollar equivalents: approximately 90 RUB = $1 USD (February 2026).
Sources: Protocol Amending the Agreement on Unified Principles and Rules for Medical Device Circulation in the EAEU of 29.12.2025; EEC Council Decision No. 46 of 12.02.2016 (Registration and Expertise Rules); EEC Council Decision No. 106 of 10.11.2017 (QMS Requirements); EEC Council Decision No. 29 of 12.02.2016 (Clinical Investigation Rules); EEC Council Decision No. 27 of 12.02.2016 (GSPR); Federal Law No. 323-FZ of 21.11.2011 (Fundamentals of Healthcare in the Russian Federation, Art. 38); GOST ISO 13485-2017.
Other articles on Regulatory Affairs →